George Shashaty, MD | Authors

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

December 01, 2006

This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.